Astellas Targets ¥4.3 Trillion Profit by 2030 as Strategic Drug Sales Double

4 articles · Updated · Bloomberg · May 26

Astellas set a five-year goal of at least ¥4.3 trillion in cumulative core operating profit before R&D expenses by fiscal 2030, banking on newer high-margin medicines.
Padcev and Izervay are central to that plan, with the company saying strategic-brand sales will double to about ¥960 billion by fiscal 2030 from ¥480 billion in fiscal 2025.
Astellas also projected roughly ¥1 trillion in pipeline revenue in the mid-2030s, extending its growth case beyond the current portfolio.
The targets underscore a strategy of shifting profit growth toward newer specialty drugs with stronger margins as the Japanese drugmaker maps out its next five years.

Can Astellas's star drugs win against rivals to replace its top seller before its 2027 patent cliff?

As Astellas chases blockbuster drugs, will patients with less profitable medical needs be left behind in its new strategy?